Multiple Sclerosis Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with Neuromyelitis Optica Spectrum Disorder (NMOSD) using internationally recognised 2015 diagnostic standards, have tested positive for a specific antibody called AQP4-IgG, and are experiencing their first episode of the condition.
- People aged 18 to 65 years old, either male or female.
- People whose level of disability, as measured by a standard neurological scale (EDSS), is scored at 7.5 or below.
- Women who are capable of becoming pregnant must have a negative pregnancy test during the screening period and must use effective contraception for the entire duration of the study.
- People who are willing to voluntarily sign a consent form agreeing to take part in the trial.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose blood test results fall outside acceptable ranges, including low white blood cell count, low neutrophil count, low haemoglobin, low platelet count, or elevated levels of creatinine, bilirubin, or certain liver enzymes (confirm with trial site for specific values).
- People who currently have active hepatitis, have a history of severe liver disease, or have blood test results indicating hepatitis B virus (HBV) infection — including those with a positive HBsAg result, or those with a negative HBsAg but positive anti-HBc antibodies whose follow-up HBV-DNA test also comes back positive.
- People who have other ongoing, active immune system conditions that require treatment with steroid medications (such as rheumatoid arthritis, scleroderma, Sjögren's syndrome, ulcerative colitis, AIDS, or immune deficiency conditions), except where a person only has positive autoantibody results with no actual symptoms of such a condition.
- Women who are pregnant, breastfeeding, or planning to become pregnant during the trial.
- People who have a history of allergic reactions to contrast dyes given by injection or to biological products derived from human sources.
- People who received a live vaccine (other than the herpes zoster vaccine) within 28 days before being randomly assigned to a treatment group in the trial.
- People who have used rituximab or other monoclonal antibody treatments within 6 months before being randomly assigned.
- People who have received intravenous immunoglobulin (IVIG) within 28 days before being randomly assigned.
- People who have previously undergone stem cell transplantation or radiation therapy targeting the lymphatic system.
- People who have recently used certain immune-suppressing medications — including azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine, methotrexate, mitoxantrone, or cyclophosphamide — unless enough time has passed since stopping them (confirm with trial site for required timeframes); people who have used leflunomide or teriflunomide must complete a specific washout process using a medication called cholestyramine before being eligible.
- People who have taken any experimental medication within 28 days or within five half-lives of that drug (whichever period is shorter) before being randomly assigned.
- People with severe mental illness that makes it clinically impossible for them to cooperate with the trial.
- People who have been diagnosed with a malignant tumour (cancer).
- People who have experienced a heart attack, unstable heart disease, stroke, or severe heart failure (classified as NYHA Class IV) within the 12 weeks before being randomly assigned.
- People who have a herpes zoster infection, or who test positive for hepatitis C (HCV) or HIV antibodies during the screening period.
- People who are unable to undergo MRI scans during the trial.
- People whom the trial investigator considers unsuitable for participation, for any reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xu Zhang, Bachelor, First Affiliated Hospital of Wenzhou Medical University
Phone: 0086-13587688130
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Primary endpoints
The change in the average daily dose of corticosteroids between the two groups during the follow-up period compared to randomization (i.e., baseline; Time to first clinical relapse
Can't join this trial?
Data last synced from ClinicalTrials.gov: 17 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.